Seattle-based Dendreon (NASDAQ: [[ticker:DNDN]]) said today that Ian Clark, the CEO of Roche’s U.S.-based Genentech unit, is resigning from the Dendreon board. Clark was named to the Dendreon board just 11 months ago, along with former Eli Lilly executive Pedro Granadillo, as part of the company’s effort to add more board expertise in sales, marketing, and manufacturing as it prepared to introduce its first product, sipuleucel-T (Provenge). Clark said in a statement today that he doesn’t have enough time anymore. “It’s been rewarding to serve on the board at one of the most exciting periods in Dendreon’s history,” Clark said in a statement. “Unfortunately, my job responsibilities currently limit the time I can devote to be an effective director to Dendreon at this time.”
